Bristol-Myers Squibb Co. (BMY) Volatility Spurs A Quest For Clarity

Currently, there are 2.02B common shares owned by the public and among those 2.02B shares have been available to trade.

The company’s stock has a 5-day price change of 5.12% and 5.90% over the past three months. BMY shares are trading 5.69% year to date (YTD), with the 12-month market performance down to -20.48% lower. It has a 12-month low price of $47.58 and touched a high of $71.07 over the same period. BMY has an average intraday trading volume of 16.72 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 3.50%, 6.77%, and -2.54% respectively.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Institutional ownership of Bristol-Myers Squibb Co. (NYSE: BMY) shares accounts for 78.44% of the company’s 2.02B shares outstanding.

It has a market capitalization of $109.66B and a beta (3y monthly) value of 0.38. The stock’s trailing 12-month PE ratio is 14.06, while the earnings-per-share (ttm) stands at $3.86. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.64% over the week and 1.97% over the month.

Analysts forecast that Bristol-Myers Squibb Co. (BMY) will achieve an EPS of $1.58 for the current quarter, $1.77 for the next quarter and $7.1 for 2025. The lowest estimate earnings-per-share for the quarter is $1.3 while analysts give the company a high EPS estimate of $1.94. Comparatively, EPS for the current quarter was $2.05 a year ago. Earnings per share for the fiscal year are expected to decrease by -9.50%, and 4.14% over the next financial year. EPS should shrink at an annualized rate of -2.80% over the next five years, compared to 5.14% over the past 5-year period.

Redburn Atlantic coverage for the Bristol-Myers Squibb Co. (BMY) stock in a research note released on February 06, 2024 offered a Neutral rating with a price target of $54. BofA Securities was of a view on January 03, 2024 that the stock is Neutral, while Cantor Fitzgerald gave the stock Neutral rating on November 15, 2023, issuing a price target of $68- $55. Deutsche Bank on their part issued Hold rating on November 09, 2023.

Most Popular

Related Posts